Patients with current deep vein thrombosis or deep vein thrombosis within the past 6 months are not eligibleXx_NEWLINE_xXPatients with a history of venous thrombotic episodes such as deep venous thrombosis, pulmonary embolus occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy; similarly, patients who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapyXx_NEWLINE_xXSTEP I: Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulationXx_NEWLINE_xXPatients with a history of any one or more of the following thromboembolic events within the past 6 months prior to study enrollment are NOT eligible for participation: \r\n* Pulmonary embolism\r\n* Untreated deep venous thrombosis (DVT)\r\n** Subjects with recent DVT who have been therapeutically coagulated for at least 6 weeks ARE eligibleXx_NEWLINE_xXSubjects with a history of venous thrombosis within the past 3 monthsXx_NEWLINE_xXPatients will be excluded if any of the following are present:\r\n* Evidence of active bleeding, intratumoral hemorrhage, or bleeding diathesis\r\n* History (within 6 months prior to study enrollment) of pulmonary embolism, deep vein thrombosis (DVT), or other venous thromboembolic event\r\n* History of hemoptysis within 6 weeks prior to study enrollmentXx_NEWLINE_xXHistory of pulmonary embolism within 6 months prior to the first dose of ALRN-6924 or untreated DVT (deep vein thrombosis)Xx_NEWLINE_xXPatients with a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to registrationXx_NEWLINE_xXHave had a prior thrombotic event (e.g., pulmonary embolism, deep vein thrombosis) or are currently receiving therapeutic or prophylactic doses of anticoagulants.Xx_NEWLINE_xXCurrent symptomatic pulmonary embolismXx_NEWLINE_xXPrior or concurrent pulmonary embolismXx_NEWLINE_xXHistory of unprovoked venous thrombosis/thromboembolismXx_NEWLINE_xXHistory of venous thromboembolism (e.g. deep venous thrombosis or pulmonary embolism) within 6 months of study entry; Note: participants enrolled after this window must be on appropriate therapeutic anticoagulationXx_NEWLINE_xXParticipants with history of pulmonary embolism, deep vein thrombosis (DVT), or vascular access related thrombosis will be allowed on study provided they are receiving adequate anticoagulation at a stable dose at the time of study entryXx_NEWLINE_xXPts must agree to take enteric-coated aspirin 81 mg orally daily, or if history of prior thrombotic disease, must be fully anticoagulated with warfarin (INR 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism (PE)at the investigator's discretionXx_NEWLINE_xXHistory of deep vein thrombosis and/or pulmonary embolus within 3 months of study entryXx_NEWLINE_xXHistory of life threatening or recurrent thrombosis/embolism; patients may participate if they are on anticoagulation during the treatmentXx_NEWLINE_xXMain portal vein tumor thrombosisXx_NEWLINE_xXThrombosis of the main portal veinXx_NEWLINE_xXHistory of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port of catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to enrollmentXx_NEWLINE_xXPresence of deep vein thrombosis based on screening lower extremity Doppler ultrasonography.Xx_NEWLINE_xXHistory of blood clots, pulmonary embolism, or deep vein thrombosis unless on adequate anticoagulant therapy as determined by the treating investigator (subject must be on stable dose for 2 weeks).Xx_NEWLINE_xXPulmonary embolism within 30 days prior to study entryXx_NEWLINE_xXPulmonary embolismXx_NEWLINE_xXActive venous thrombosis with contraindication for anticoagulationXx_NEWLINE_xXCurrent treatment with therapeutic doses of Coumadin-derivative anticoagulants (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed)Xx_NEWLINE_xXPatients determined to be at increased risk of arterial or venous thrombosis by the investigatorXx_NEWLINE_xXHistory of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past 6 monthsXx_NEWLINE_xXPatient must not have any thromboembolic event (deep vein thrombosis or pulmonary embolism) less than 3 weeks prior to enrollmentXx_NEWLINE_xXHistory of deep venous thrombosis, clinically significant peripheral vascular disease, or other thrombotic eventXx_NEWLINE_xXDeep vein thrombosis or pulmonary embolism =< 4 weeks before first dose of protocol-indicated treatment, unless adequately treated and stable.\r\n* Patients receiving therapeutic non-coumarin anticoagulation are eligible, provided they are on a stable dose (per investigator judgment) of anticoagulant.Xx_NEWLINE_xXA diagnosis of deep vein thromboses in the preceding four weeks of study enrollment.Xx_NEWLINE_xXHistory of thromboembolic events (including both pulmonary embolism and deep venous thrombus but not including tumor thrombus) within the last 6 monthsXx_NEWLINE_xXActive thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stableXx_NEWLINE_xXDeep vein thrombosis (DVT) / pulmonary embolism (PE) in the past 6 months prior to randomizationXx_NEWLINE_xXThrombotic events (pulmonary embolism; deep venous thrombosis) within 6 month prior to start of therapyXx_NEWLINE_xXHave been treated for a deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke within the past 6 months (may be extended to 1 year if medically indicated per physician discretion).Xx_NEWLINE_xXThromboembolic events and/or bleeding disorders ? 14 days (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) prior to the first dose of study drugXx_NEWLINE_xXPatients unwilling to take deep vein thrombosis (DVT) prophylaxis.Xx_NEWLINE_xXHistory of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment.Xx_NEWLINE_xXSymptomatic pulmonary embolism within 6 months prior to study entryXx_NEWLINE_xXMain portal vein thrombosis (Vp4) as documented on imagingXx_NEWLINE_xXIf prior history of deep vein thrombosis (DVT)/pulmonary embolism (PE), the patient needs to be on stable doses of anticoagulation with low molecular weight heparin or oral anticoagulant for at least two weeksXx_NEWLINE_xXInternal jugular venous thrombosis, acute or within 3 months.Xx_NEWLINE_xXActive thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stableXx_NEWLINE_xXHistory or presence within the last 3 months of Deep Vein Thrombosis (DVT) or a pulmonary embolism (PE);- Uncontrolled leptomeningeal disease;Xx_NEWLINE_xXSubject has a history of non-central line related thrombosis (arterial or venous), more than one prior central-line related thrombosis or known coagulopathy.Xx_NEWLINE_xXhave a history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism or retinal vein thrombosis, unless currently on anticoagulant therapy;Xx_NEWLINE_xXPulmonary embolism (PE) in the 3 months before enrollment; anticoagulation is permitted as long as stable dosage for more than 3 monthsXx_NEWLINE_xXRecent occurrence (within 3 to 6 months) of a major thromboembolic event, such as pulmonary embolism or proximal deep vein thrombosis, unless stable on (>1 month) therapeutic anticoagulation (aspirin <325 milligrams (mg) daily or low-molecular-weight heparin [LMWH]). Participants with a history of clinically non-significant thromboembolic events, not requiring anticoagulation, are allowed on study.Xx_NEWLINE_xXSubject has active or history of deep vein thrombosis (DVT)Xx_NEWLINE_xXPatient with a history of thromboembolic disease to include pulmonary embolus or other extremity deep venous thrombosisXx_NEWLINE_xXAny history of arterial or venous thrombosis/thromboembolic event, including pulmonary embolism within the past 12 months prior to registration.Xx_NEWLINE_xXHistory of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollmentXx_NEWLINE_xXVenous thrombotic events (eg, deep vein thrombosis) or pulmonary arterial events (eg, pulmonary embolism) within 3 months before the first dose of study drug. Patients with venous thrombotic events ?3 months before the first dose of study drug on stable anticoagulation therapy are eligible.Xx_NEWLINE_xXPulmonary embolism.Xx_NEWLINE_xXThromboembolic event (e.g., deep vein thrombosis [DVT] and pulmonary embolism [PE]) ? 4 weeks of C1D1.Xx_NEWLINE_xXHas a history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment periodXx_NEWLINE_xXComplete portal vein thrombosis on CT scansXx_NEWLINE_xXDeep vein thrombosis (DVT) or pulmonary embolus which require use of oral anticoagulants or, if on low molecular weight heparin, have not been on a stable dose for at least 2 weeksXx_NEWLINE_xXPrior or concurrent deep vein thrombosis or pulmonary embolismXx_NEWLINE_xXHistory of arterial thrombosis; patients with history of deep vein thrombosis (DVT) are eligible as long as they have received or are receiving appropriate anticoagulation therapyXx_NEWLINE_xXPatients with documented deep venous thrombosis or pulmonary embolism within the past 3 monthsXx_NEWLINE_xXPatients who have a history of deep vein thrombosis or pulmonary embolus and are stable on anticoagulation for > 1 month are eligibleXx_NEWLINE_xXHistory of deep vein thrombosis or pulmonary embolism within 6 month of anticipated starting of axitinibXx_NEWLINE_xXThe patient has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to randomizationXx_NEWLINE_xXHistory of arterial thrombosis within 3 months of starting study treatmentXx_NEWLINE_xXConcurrent medical problems that preclude use of deep vein thrombosis (DVT) prophylaxis with lenalidomide treatmentXx_NEWLINE_xXPatients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of\r\nstudy enrollment)Xx_NEWLINE_xXMyocardial infarction, uncontrolled angina, congestive heart failure, or cerebrovascular accident within previous 6 months; subjects with a history of deep vein thrombosis or pulmonary embolism, at provider discretionXx_NEWLINE_xXThe patient has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism, including portal venous thrombosis (venous port or catheter thrombosis, incidental pulmonary embolism diagnosed on imaging studies or superficial venous thrombosis are not considered significant) during the 3 months prior to randomizationXx_NEWLINE_xXSubjects with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 6 months of study treatment initiationXx_NEWLINE_xXAny of the following in the previous 6 months: deep vein thrombosis or symptomatic pulmonary embolismXx_NEWLINE_xXUnable or unwilling to take any prophylaxis; patients with history of or new/active deep vein thrombosis/embolism/thrombophilia are allowed to participate if they are on appropriate therapeutic anticoagulation during the treatment on the trial; these patients would not need the aspirin with the lenalidomide unless clinically indicated; therefore, patients must be able and willing to receive anticoagulation (prophylaxis versus therapeutic as clinically indicated)Xx_NEWLINE_xXHas had a symptomatic venous thrombosis within 2 weeks prior to study enrollment - NOTE: Subjects with a history of a deep vein thrombosis >2 weeks prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this studyXx_NEWLINE_xXVenous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 6 months prior to enrollmentXx_NEWLINE_xXHistory of deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months before enrollmentXx_NEWLINE_xXSubjects with a history of pulmonary embolism are excludedXx_NEWLINE_xXPulmonary embolismXx_NEWLINE_xXsignificant cardiovascular disease within the last 3 months: including myocardial infarction, unstable angina, congestive heart failure, ongoing arrhythmias of Grade > 2 , thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism). Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.Xx_NEWLINE_xXHistory of deep venous thrombosis and pulmonary embolism (Phase 1b).Xx_NEWLINE_xXHistory of deep venous thrombosis (DVT) or pulmonary embolism (PE)Xx_NEWLINE_xXHas a history of blood clots, pulmonary embolism, or DVT unless controlled by anticoagulant treatmentXx_NEWLINE_xXHistory of arterial thromboembolic events or symptomatic pulmonary embolism within the past 6 monthsXx_NEWLINE_xXPatients with history of recurrent venous thromboembolism (deep venous thrombosis or pulmonary embolism) or history of venous thromboembolism within 6 months prior to registration on study will not be eligibleXx_NEWLINE_xXPatients with a recent history of deep vein thrombosis or pulmonary embolus, in the six months prior to enrollment are not eligible for this studyXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack, pulmonary embolism (including asymptomatic or previously treated pulmonary embolism [PE]), or untreated deep venous thrombosis within the past 6 months; patients with recent deep vein thrombosis (DVT) who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligibleXx_NEWLINE_xXRecent venous thrombosis within 4 weeks prior to study registration; patients at high risk for thrombotic events due to inherited risk factors (i.e. factor V Leiden) or deep vein thrombosis (DVT)/pulmonary embolism (PE) in the past 12 months should be on secondary prophylaxis with anti-coagulant therapy (i.e. warfarin or low molecular weight heparin) prior to enrollmentXx_NEWLINE_xXHave portal or hepatic vein tumor invasion/thrombosis.Xx_NEWLINE_xXPatients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to initiate prophylaxis with low molecular weight heparinXx_NEWLINE_xXPatients with any of the following within 6 months of enrollment: deep vein thrombosis, pulmonary embolus, myocardial infarction, cerebrovascular accident, unexplained loss of consciousnessXx_NEWLINE_xXDeep vein thrombosis or pulmonary embolism within 3 months of study entryXx_NEWLINE_xXPatients must agree to take enteric coated aspirin 81 mg orally daily, or if history of prior thrombotic disease, must be fully anticoagulated with warfarin (international normalized ratio [INR] 2-3) or be treated with full dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism (PE)Xx_NEWLINE_xXHistory of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the 3 months prior to randomizationXx_NEWLINE_xXPatients must not have been previously diagnosed with a deep venous or arterial thrombosis (including pulmonary embolism), and must not have a known thrombophilic conditionXx_NEWLINE_xXPatients with a history of arterial or venous thrombosisXx_NEWLINE_xXPatients with history of deep venous thrombus or pulmonary embolism. Patients who are at increased risk of thrombosis during treatment with lenalidomide including those taking concurrent erythropoietin, darbepoetin or high-dose corticosteroids are also excluded.Xx_NEWLINE_xXHistory of deep vein thrombosis and/or pulmonary embolism within 4 weeks of enrollment.Xx_NEWLINE_xXActive thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stableXx_NEWLINE_xXHistory of venous or arterial thrombosis within the preceding year of enrollmentXx_NEWLINE_xXHave any serious or unstable concomitant systemic conditions that are incompatible with this clinical study, including but not limited to substance abuse, psychiatric disturbance, or uncontrolled intercurrent illness (including active infection), arterial thrombosis, or symptomatic pulmonary embolismXx_NEWLINE_xXThrombotic or embolic event within the last 6 months including portal vein thrombosisXx_NEWLINE_xXActive thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to first administration of study drug unless adequately treated and considered by the Investigator to be stable.Xx_NEWLINE_xXPrior history of deep venous thrombosis or pulmonary embolism within 5 years prior to enrollment in the study and not currently on systemic anticoagulationXx_NEWLINE_xXDeep vein thrombosis or pulmonary embolism =< 4 weeks before first dose of protocol-indicated treatment, unless adequately treated and stableXx_NEWLINE_xXHistory of unprovoked deep vein thrombosis/pulmonary embolism (DVT/PE) in past twelve (12) monthsXx_NEWLINE_xXPatients with a history of idiopathic deep venous thrombosis, pulmonary embolus, thrombotic stroke, or arterial thrombosis will be excluded from study; patients with a history of a central venous catheter-associated thrombosis that has completely resolved will be eligible for study but should be monitored for thrombosisXx_NEWLINE_xXHistory of vascular disease (e.g. deep vein thrombosis, stroke)Xx_NEWLINE_xXPatients at high-risk for thromboembolic disease, such as those with prior heterotopic ossification (h/o) deep venous thrombosis (DVT).Xx_NEWLINE_xXAcute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for at least 4 weeks prior to first IMP administration.Xx_NEWLINE_xXPatients with any prior history of arterial thrombosis or symptomatic pulmonary embolismXx_NEWLINE_xXPatients must not have a history of prior stroke, transient ischemic attack (TIA), pulmonary embolism, or untreated deep vein thrombosis\r\n* NOTE: Patients may be eligible if they have received at least 3 months of anticoagulation for a deep vein thrombosisXx_NEWLINE_xXHistory of deep vein thrombosis or pulmonary embolism within 6 months of screening; patients who are currently taking anticoagulation therapy for a prior history (> 6 months from screening) of thrombosis may still be eligibleXx_NEWLINE_xXPatients with a history of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or insufficiently treated deep venous thrombosis (DVT) within the past 3 months; Note: Participants with recent DVT who have been treated with therapeutic anti-coagulants for at least 6 weeks are eligible, with the exception of participants being treated with warfarin, which is prohibited on this study; other oral anti-coagulants may be allowed after discussion with overall principle investigator (PI), but short half-life low molecular weight heparins are strongly preferredXx_NEWLINE_xXPatients with a history of venous or arterial thrombosis personally before the age of 40 years unless associated with a central lineXx_NEWLINE_xXAny of the following conditions =< 6 weeks prior to registration:\r\n* Cerebrovascular accident (CVA)\r\n* Admission for unstable angina\r\n* Cardiac angioplasty or stenting or coronary artery bypass graft surgery\r\n* Untreated pulmonary embolism or untreated deep venous thrombosis (DVT)\r\n* Arterial thrombosis\r\n* Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification systemXx_NEWLINE_xXHistory of blood clots, pulmonary embolism, or deep vein thrombosis in previous 6 months unless controlled by anticoagulant treatmentXx_NEWLINE_xXPrior history of a major thrombotic event, such as pulmonary emboli, deep vein thrombosis or stroke, as assessed by the investigator, or history of an asparaginase associated serious hemorrhage or thrombus requiring anticoagulation therapyXx_NEWLINE_xXPatients with evidence of active bleeding, intratumoral hemorrhage, or bleeding diathesis are not eligible:\r\n* History (within 180 days prior to study enrollment) of arterial thromboembolic events, including transient ischemic attack (TIA) or cerebrovascular accident (CVA)\r\n* History (within 180 days prior to study enrollment) of pulmonary embolism, deep vein thrombosis (DVT), or other venous thromboembolic event\r\n* History of hemoptysis within 42 days prior to study enrollmentXx_NEWLINE_xXPulmonary embolismXx_NEWLINE_xXHistory of pulmonary embolus and/or substantial deep vein thrombosisXx_NEWLINE_xXAny history of a venous thromboembolic event (VTE), including deep vein thrombosis\n             (DVT) or pulmonary embolism (PE)Xx_NEWLINE_xXPatients must not have had significant vascular disease (eg, aortic aneurysm requiring surgical repair, deep venous or arterial thrombosis) within the last 6 months prior to study entryXx_NEWLINE_xXSplanchnic vein thrombosis (includes Budd-Chiari, portal vein, splenic and mesenteric thrombosis)Xx_NEWLINE_xXHas had a symptomatic venous thrombosis within the 14 days prior to study enrollment - NOTE: Subjects with a history of a deep vein thrombosis 14 days prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this studyXx_NEWLINE_xXPatients may have a history of current or previous deep vein thrombosis or pulmonary embolism but are required to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulationXx_NEWLINE_xXPrevious history of pulmonary embolism or pulmonary embolism found on screening exam.Xx_NEWLINE_xXThey have a history of a venous or arterial thrombosis that was not associated to a central line.Xx_NEWLINE_xXHistory of arterial thromboembolic events or symptomatic pulmonary embolism within 6 months of study enrollmentXx_NEWLINE_xXThe patient has a history of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered \significant\) during the 3 months prior to first dose of protocol therapyXx_NEWLINE_xXPatient must have no history of venous thrombosis within 12 weeks of randomizationXx_NEWLINE_xXHistory of cerebrovascular accident including transient ischemic attack, pulmonary embolism (PE) (including asymptomatic or previously treated PE), or untreated deep venous thrombosis within the past 6 months; patients with deep venous thrombosis (DVT) who are being treated with therapeutic anti-coagulating agents are eligibleXx_NEWLINE_xXHistory of pulmonary embolism within 6 months prior to the first dose of ALRN-6924 or untreated DVT (deep vein thrombosis)Xx_NEWLINE_xXHas had within the past 6 months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (NCI CTCAE Grade 3 or 4), chronic liver disease (meeting criteria for Child-Pugh Class B or C), or organ transplantation.Xx_NEWLINE_xXPulmonary LCNEC;Xx_NEWLINE_xXHistory of thromboembolic events and/or bleeding disorders ? 14 days (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) prior to the first dose of study drugXx_NEWLINE_xXHas a history of deep vein thrombosis or pulmonary embolism within 6 months of screening.Xx_NEWLINE_xXHistory of untreated deep venous thrombosisXx_NEWLINE_xXAbsence of history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia; patients with a history of deep vein thrombosis(DVT)/pulmonary embolism (PE) or thrombophilia may participate if they are willing to be on full anticoagulation during the treatment if randomized to rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R2CHOP) arm A; full anticoagulation is defined as warfarin, factor X inhibitors, or low molecular weight heparin at therapeutic dosesXx_NEWLINE_xXHas had a deep venous thrombosis (DVT) or pulmonary embolism within the 3 months prior to study enrollment. NOTE: Subjects with a history of a DVT or pulmonary embolism >3 months prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study.Xx_NEWLINE_xXhave a history of deep venous thrombosis/embolism and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment periodXx_NEWLINE_xXMain portal vein thrombosisXx_NEWLINE_xXPatients with the following: \r\n* Bleeding diathesis or patients in whom prophylactic antithrombotic therapy is otherwise contraindicated \r\n* Patients with prior deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial thromboembolism \r\n* Patients with ischemic stroke or transient ischemic attack (TIA)Xx_NEWLINE_xXPulmonary embolism.Xx_NEWLINE_xXPulmonary embolism within 12 months before screeningXx_NEWLINE_xXHave a history of arterial or venous embolism within 6 months prior to study entry.Xx_NEWLINE_xXIndicated for radical prostatectomy\r\n* Note: candidates for radical prostatectomy are still eligible even if they have a history of deep venous thrombosis, pulmonary embolism, and/or cerebrovascular accident or currently requiring systemic anticoagulationXx_NEWLINE_xXParticipants with prior history of thromboembolic disease (i.e. deep venous thrombosis [DVT] or pulmonary embolism [PE] within the last six months)Xx_NEWLINE_xXHistory of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment.Xx_NEWLINE_xXHave a history of deep vein thrombosis, pulmonary embolism, or any other significant venous thromboembolism (venous catheter thrombosis or superficial venous thrombosis not considered \significant\) during the 3 months prior to study enrollment. Participants with venous thromboembolism occurring 3 to 6 months prior to study enrollment are allowed, if being treated with low molecular weight heparin.Xx_NEWLINE_xXHistory of deep venous thrombosis or migratory thrombophlebitis (Trousseau)Xx_NEWLINE_xXConditions contraindicated to progesterone treatment (including, but not limited to, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of stroke, allergy to peanuts, hypersensitive to progesterone and liver dysfunction)Xx_NEWLINE_xXKnown, existing uncontrolled coagulopathy; patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation are eligible IF: they are appropriately anticoagulated and have not had a grade 2 or greater bleeding episode in the 3 weeks before day 1Xx_NEWLINE_xXHas a history of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment (patient must be on stable dose for 2 weeks).Xx_NEWLINE_xXDeep vein thrombosis (DVT)/pulmonary embolism (PE) in the past 6 monthsXx_NEWLINE_xXHistory of recurrent thrombosis or any thrombosis within the past 6 monthsXx_NEWLINE_xXAcute thrombosis within 3 months of screeningXx_NEWLINE_xXHistory of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment.Xx_NEWLINE_xXHave had a new pulmonary embolism, extremity deep venous thromboembolism, or portal vein thrombosis within 2 months of study enrollment (any thrombosis within 2 months of study enrollment must be approved by the protocol chair and/or medical monitor)Xx_NEWLINE_xXPatients with prior deep vein thrombosis (DVT) or pulmonary embolism (PE) currently on anticoagulation regimen will be permittedXx_NEWLINE_xXThrombosis or vascular ischemic events within the last six months, such as deep venous thrombosis, pulmonary embolism, transient ischemic attack, cerebral infarction, or myocardial infarctionXx_NEWLINE_xXHistory of thromboembolic events (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) ? 2 weeks before the first dose of study drug and/or clinical diffuse intravascular coagulation (DIC)Xx_NEWLINE_xXPatients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation and who meet any of the following criteria:\r\n* Have been on a stable dose of anticoagulation for < 1 month\r\n* Have had a grade 2, 3 or 4 hemorrhage in the last 30 days\r\n* Are experiencing continued symptoms from their venous thromboembolic event (e.g. continued dyspnea or oxygen requirement); NOTE: Patients who have had a venous thromboembolic event but do not meet any of the above three criteria are eligible for participationXx_NEWLINE_xXIn past 6 months: deep vein thrombosis or pulmonary embolismXx_NEWLINE_xXPatients with known tumor thrombus or deep vein thrombosis are eligible if stable on low molecular weight heparin for ?4 weeks.Xx_NEWLINE_xXPatients with a history of deep venous thromboembolism or pulmonary embolism on treatment with anticoagulation are eligible for the studyXx_NEWLINE_xXHistory of arterial thrombosis (i.e. stroke) in the past yearXx_NEWLINE_xXHistory of venous thrombosis currently requiring anti-coagulation therapyXx_NEWLINE_xXThe patient has a known history of stroke, myocardial infarction, peripheral vascular disease, or recent (within 3 months) uncontrolled deep venous thrombosis.Xx_NEWLINE_xXPART B: Any history of venous or arterial thrombo-embolism, or previous revascularization procedureXx_NEWLINE_xXMain portal vein thrombosis (PVT)Xx_NEWLINE_xXHistory of arterial thrombosis (i.e. stroke) in the past yearXx_NEWLINE_xXHistory of venous thrombosis currently requiring anti-coagulation therapyXx_NEWLINE_xXEvidence of deep vein thrombosis (DVT) or pulmonary embolism (PE) or other known thromboembolic event present during screening period.Xx_NEWLINE_xXKnown history of deep vein thrombosis or pulmonary embolus except in patients where the cause was directly related to foreign body implants, i.e. central venous catheters, portacaths, etc.Xx_NEWLINE_xXHistory of thrombosis or thromboembolic event within last 30 days prior to study entryXx_NEWLINE_xXPatients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of study enrollment)Xx_NEWLINE_xXPulmonary embolism on active therapyXx_NEWLINE_xXSubjects with deep vein thrombosis (DVT) and Pulmonary embolism (PE) within 3 months prior to day 1 treatmentXx_NEWLINE_xXVenous thromboembolic events (e.g., deep vein thrombosis or pulmonary embolism) within 6 months of screeningXx_NEWLINE_xXHistory of pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: Patients with recent DVT who have been treated with therapeutic anticoagulation including Coumadin or any low molecular weight heparin for at least 6 weeks are eligibleXx_NEWLINE_xXCandidates may have a history of deep vein thrombosis, pulmonary embolism, and/or cerebrovascular accident, or require concomitant systemic anticoagulation, if otherwise deemed to be suitable for RPXx_NEWLINE_xXHistory or clinical evidence of deep venous thrombosis including pulmonary embolus within 6 months of treatmentXx_NEWLINE_xXPatient at high risk for deep vein thrombosis not willing to take DVT prophylaxis.Xx_NEWLINE_xXHistory of pulmonary embolism or deep vein thrombosis (DVT) within the past 6 monthsXx_NEWLINE_xXHistory of cerebrovascular accident (CVA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: subjects with recent DVT who have been treated with therapeutic anti-coagulant agents for at least 6 weeks are eligibleXx_NEWLINE_xXHistory of pulmonary embolism or deep venous thrombosis within the past six months of the first dose of study treatmentXx_NEWLINE_xXPatients with a history of deep vein thrombosis must be on anti-coagulation therapy prior to enrollment; patients requiring prophylactic anti-coagulation are eligibleXx_NEWLINE_xXPatients with history of deep venous thrombus or pulmonary embolism; patients who are at increased risk of thrombosis during treatment with Revlimid including those taking concurrent erythropoietin, darbepoetin or high-dose corticosteroids are also excludedXx_NEWLINE_xXPatients must not have had a deep venous or arterial thrombosis (non-central venous catheter related) within the last three months prior to study entryXx_NEWLINE_xXHistory of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligibleXx_NEWLINE_xXEXPANSION COHORT ONLY: History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligibleXx_NEWLINE_xXThe participant has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin or sudden cardiac arrest. Any participant with a history of venous thromboembolism (VTE) (for example, deep vein thrombosis [DVT] of the leg or arm and/or pulmonary embolism) will be excluded.Xx_NEWLINE_xXThromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months prior to enrollment.Xx_NEWLINE_xXHistory of life threatening or recurrent thrombosis/embolism; subjects may participate if they are adequately anticoagulated during the treatmentXx_NEWLINE_xXDocumented deep vein thrombosis within 1 year before enrollment on the study, except if upper arm thrombosis related to central venous catheters, within 3 months before enrollment on the studyXx_NEWLINE_xXHistory of deep venous or arterial thrombotic disease (including but not limited to, acute myocardial infarction due to coronary thrombosis, ischemic stroke, and peripheral arterial disease), unless:\r\n* Line-related thrombosis without embolus\r\n* Occurring >= 1 year prior to screeningXx_NEWLINE_xXPatients with a history of deep venous thrombosis, pulmonary embolism, and/or cerebrovascular accident or currently requiring systemic anticoagulation are eligible provided they are determined to be candidates for radical prostatectomyXx_NEWLINE_xXPortal vein thrombosis of bland or malignant origin.Xx_NEWLINE_xXDeep vein thrombosis in the preceding 2 months.Xx_NEWLINE_xXUnstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event =< 30 days before enrollmentXx_NEWLINE_xXHistory of arterial or venous embolism within 3 months prior to study enrollment. If the embolism occurred >3 and <6 months, the participant is eligible provided appropriate treatment according to institutional standard of care is ensured.Xx_NEWLINE_xXPulmonary:Xx_NEWLINE_xXPrevious history of pulmonary embolism or pulmonary embolism found on screening exam.Xx_NEWLINE_xXPatients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of study enrollment)Xx_NEWLINE_xXNo prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to enrollment in the studyXx_NEWLINE_xXPulmonary embolism, deep vein thrombosis, or other significant venous event =< 8 weeks before enrollmentXx_NEWLINE_xXEvidence of hepatic vein invasion or caval thrombosisXx_NEWLINE_xXHistory of suspected history, or presence of heparin induced toxicity (w/ or w/o thrombosis)Xx_NEWLINE_xXHas had within the past 6 months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (CTC Grade 3 or 4), chronic liver disease (meeting criteria for Child-Pugh Class B or C), a second active malignancy (excluding basal cell carcinoma and cervical carcinoma in situ), organ transplantation.Xx_NEWLINE_xXHistory of deep venous thromboses or pulmonary embolism =< 365 days prior to registrationXx_NEWLINE_xXHave a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolic event during the 3 months prior to receiving study drugs.Xx_NEWLINE_xXHistory of arterial or deep venous thromboembolism within the 12 months prior to enrollmentXx_NEWLINE_xXDocumented deep venous thrombosisXx_NEWLINE_xXPrevious pulmonary embolism within 12 months before study entryXx_NEWLINE_xXOccurrence of deep vein thrombosis within 4 weeks, prior to study entryXx_NEWLINE_xXThromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months of screeningXx_NEWLINE_xXHistory of heart problems or thrombosis within 6 months prior to study start.Xx_NEWLINE_xXPrevious pulmonary embolism within 12 months prior to study entryXx_NEWLINE_xXDeep vein thrombosis diagnosed within 3 monthsXx_NEWLINE_xXHistory within 3 months of deep vein thrombosis, pulmonary embolism, or strokeXx_NEWLINE_xXDiagnosed active deep vein thrombosis (DVT) that has not been therapeutically anticoagulatedXx_NEWLINE_xXClinical evidence of severe peripheral vascular disease, diabetic ulcers or venous stasis ulcers, or history of deep venous or arterial thrombosis within 3 months prior to screeningXx_NEWLINE_xXHistory of thromboembolic events and bleeding disorders ?3 months (e.g., (deep vein thrombosis) DVT or pulmonary embolism (PE))Xx_NEWLINE_xXPatients with a history of deep vein thrombosis or thromboembolism within < 6 months prior to starting study treatmentXx_NEWLINE_xXKnown arterial or venous thrombosis or pulmonary embolism within 2 yearsXx_NEWLINE_xXPrior or concurrent deep vein thrombosis or pulmonary embolismXx_NEWLINE_xXThrombosis or vascular ischemic events within the last twelve months, such as deep venous thrombosis, pulmonary embolism, transient ischemic attack, cerebral infarction, or myocardial infarctionXx_NEWLINE_xXHistory of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligibleXx_NEWLINE_xXNo thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of registration for protocol therapy.Xx_NEWLINE_xXHistory of deep vein thrombosis or pulmonary embolism.Xx_NEWLINE_xXPatients with a history of deep vein thrombosis or thromboembolism within < 6 months prior to starting study treatmentXx_NEWLINE_xXHistory of main or lobar portal vein thrombosisXx_NEWLINE_xXPulmonary embolus or thrombosis of the deep venous system (deep vein thrombosis [DVT]) within 2 weeks of starting study treatment; patients who had a history of thromboembolic disease should be stable on therapeutic anticoagulation using low molecular weight (LMW) heparin for at least 2 weeks prior to the start of study treatment; use of warfarin (or derivatives) is not allowed at the start of study treatmentXx_NEWLINE_xXHistory of life threatening or recurrent thrombosis/embolism; patients may participate if they are on anticoagulation during the treatmentXx_NEWLINE_xXHistory of pulmonary embolism (PE), or untreated deep venous thrombosis (DVT) =< 180 daysXx_NEWLINE_xXPatient is in need of anticoagulation therapy except for low-dose heparin or low-dose coumadin for maintenance of patency of central venous access or prevention of deep vein thrombosis (DVT)Xx_NEWLINE_xXPatients must not have a prior history of deep vein thrombosis (DVT) or pulmonary embolism in the past 5 yearsXx_NEWLINE_xXPatients who have had a deep vein thrombosis or pulmonary embolus within the past 6 months are eligible if they are on stable therapeutic anticoagulationXx_NEWLINE_xXSuspected or diagnosed deep vein thrombosis or painful foot neuropathy.Xx_NEWLINE_xXPulmonary embolism (PE) within the last 6 months prior to registrationXx_NEWLINE_xXCurrent venous thrombosis in either upper extremity or be on current anticoagulant therapyXx_NEWLINE_xXActive deep vein thrombosis in the treatment extremityXx_NEWLINE_xXDeep venous thrombosis (DVT) diagnosed within 12 months of study enrollment or history or untreated lower extremity DVT, bone metastases, currently active skin infection, or lymphedema currently involving the treatment fieldXx_NEWLINE_xXHistory of arterial or venous thrombosis (excluding line-thrombosis) within the last 1 year, or those with known inherited coagulopathies; arterial or venous thrombosis includes pulmonary embolism, deep vein thrombosis of both upper (excluding line-thrombosis) and lower extremities, coronary artery disease managed medically or requiring intervention (percutaneous stent placement or coronary bypass surgery), cerebrovascular accident (for transient ischemic attacks clinical documentation is required), or involvement of other organs (such as hepatic, renal, spleen or other sites)Xx_NEWLINE_xXArterial or venous thrombosis in the last year except for line-related venous thrombosis more than 3 months agoXx_NEWLINE_xXDiagnosis of acute pulmonary embolism within past 2 weeksXx_NEWLINE_xXHistory of deep vein thrombosis (DVT) in the lymphedematous upper extremityXx_NEWLINE_xXHistory of a deep venous thrombosis or a thromboembolismXx_NEWLINE_xXParticipant has had pulmonary embolism or any other thrombo-embolic event within 6 months prior to study entryXx_NEWLINE_xXDiagnosis of acute pulmonary embolism within past 2 weeksXx_NEWLINE_xXPatients with existing deep venous thrombosis will be excludedXx_NEWLINE_xXPatients with a recent history of deep vein thrombosis (DVT) or pulmonary embolus (PE), in six months prior to enrollment are not eligible for this studyXx_NEWLINE_xXHistory of deep venous thrombosis or embolic event (eg, pulmonary embolism) within 6 months prior to randomization.Xx_NEWLINE_xXHistory of thrombosis, deep vein thrombosis, pulmonary emboli, or embolic stroke AND have not been stable on anticoagulants within the past 6 months; local central line thrombosis is allowedXx_NEWLINE_xXOngoing use or planned peri-operative use of anticoagulants (not including deep vein thrombosis [DVT] prophylaxis)Xx_NEWLINE_xXWithin the past 6 months:\r\n* Acute pulmonary embolus\r\n* Deep vein thrombosisXx_NEWLINE_xXCONTROL (HEALTHY) GROUP: Within the past 6 months:\r\n* Acute pulmonary embolus\r\n* Deep vein thrombosisXx_NEWLINE_xXConditions that could cause swelling (e.g., pregnancy, congestive heart failure, chronic/acute renal disease, cor pulmonale, nephrotic syndrome, nephrosis, liver failure or cirrhosis, pulmonary edema, and thrombophlebitis, or deep vein thrombosis in armsXx_NEWLINE_xXIndividuals with history of myocardial infarction, stroke, coronary-artery bypass draft, invasive coronary revascularization, arrhythmia requiring treatment such as atrial fibrillation, congestive heart failure, peripheral vascular disease, pulmonary embolism, or deep venous thrombosis.Xx_NEWLINE_xXMedical conditions:\r\n* Have a predisposition to or prior history of thromboembolism, deep venous thrombosis, pulmonary embolism, or stroke\r\n* History of renal or liver disease\r\n* Prior ovarian or endometrial cancer\r\n* Stopped or started hormone replacement within 8 weeks\r\n* Any other condition or intercurrent illness that in the opinion of the investigator makes the woman a poor candidate for RPFNA.Xx_NEWLINE_xXArterial or venous thrombosis requiring active anticoagulation; (if a patient has a history of arterial or venous thrombosis and has completed anticoagulation therapy, then he/she is not excluded)Xx_NEWLINE_xXKnown history of VTE prior to diagnosis (deep vein thrombosis [DVT] or pulmonary embolism PE) due to increased underlying risk of new eventXx_NEWLINE_xXHistory of blood clots (i.e. pulmonary embolism, deep vein thrombosis [DVTs])Xx_NEWLINE_xXHistory of deep vein thrombosis or pulmonary embolism within 4 weeks of first study doseXx_NEWLINE_xXHistory of therapeutic doses of anticoagulants including warfarin and low molecular weight heparin (e.g. for prior deep venous thrombosis and pulmonary embolism) in the preceding yearXx_NEWLINE_xXHistory of: Thrombophelitis, Deep vein thrombosis, Pulmonary embolus, Clotting disorder, Bleeding disorder, Heart disease, Diabetes, Stroke, Peanut allergy, Liver dysfunction, Hypersensitivity to progesteroneXx_NEWLINE_xXacute pulmonary embolism or pulmonary infarction,Xx_NEWLINE_xXOcclusive main portal vein thrombosisXx_NEWLINE_xXPatients with thrombosis within the splenic veinXx_NEWLINE_xXMain or segmental portal vein thrombosisXx_NEWLINE_xXPatients with severe emphysema, pulmonary vasculitis, pulmonary hypertension, respiratory distress syndrome, or a history of pulmonary embolism.Xx_NEWLINE_xXPatient must not have had significant vascular disease (e.g., Moya-Moya, aortic aneurysm requiring surgical repair, deep venous or arterial thrombosis) =< 6 months prior to study entryXx_NEWLINE_xXSymptomatic deep vein thrombosis or pulmonary embolism within last 6 monthsXx_NEWLINE_xXPatients who have a history of venous or arterial thromboembolic events including pulmonary embolism, deep venous thrombosis and strokeXx_NEWLINE_xXNo thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of starting IFN gammaXx_NEWLINE_xXPatients who will require anticoagulant medications other than routine deep vein thrombosis (DVT) prophylaxis within 8 days postoperativelyXx_NEWLINE_xXHistory of deep vein thrombosis or pulmonary embolism.Xx_NEWLINE_xXParticipants requires the use of warfarin (use in prophylactic doses [example, deep vein thrombosis prophylaxis]) is allowed.Xx_NEWLINE_xXSubjects with stroke, arterial or venous thrombosis within 6 months not eligibleXx_NEWLINE_xXActive deep venous thrombosis, pulmonary embolism, retinal vascular thrombosis, and any arterial thrombosis including stroke and myocardial infarction or history of these conditionsXx_NEWLINE_xX